U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C32H38Cl2N10O4.ClH
Molecular Weight 734.076
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALLIMUSTINE HYDROCHLORIDE

SMILES

Cl.CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC(NC(=O)C4=CC=C(C=C4)N(CCCl)CCCl)=CN3C)=CN2C)C=C1C(=O)NCCC(N)=N

InChI

InChIKey=BLSOATWWAGIRGE-UHFFFAOYSA-N
InChI=1S/C32H38Cl2N10O4.ClH/c1-41-18-22(14-25(41)30(46)37-11-8-28(35)36)39-32(48)27-16-23(19-43(27)3)40-31(47)26-15-21(17-42(26)2)38-29(45)20-4-6-24(7-5-20)44(12-9-33)13-10-34;/h4-7,14-19H,8-13H2,1-3H3,(H3,35,36)(H,37,46)(H,38,45)(H,39,48)(H,40,47);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C32H38Cl2N10O4
Molecular Weight 697.615
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tallimustine (also known as FCE 24517), an alkylating benzoyl mustard derivative of distamycin A that was studied as an anti-tumor agent. Tallimustine participated in phase I clinical trial in patients with advanced cancer. As a result, the was obtained the recommended Phase II dosage for tallimustine. However, the further development of this drug was discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
1998 Jan
Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine.
2001 Jun
Patents

Patents

Sample Use Guides

Patients with advanced solid tumors received i.v. bolus injections of tallimustine daily for 3 consecutive days. Patients were treated at six dosage levels of 33.3 micrograms/m2/day to 250 micrograms/m2/day for 3 consecutive days, with courses of therapy repeated every 28 days
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:39:14 GMT 2023
Edited
by admin
on Fri Dec 15 15:39:14 GMT 2023
Record UNII
JWV8AC9E4V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TALLIMUSTINE HYDROCHLORIDE
Common Name English
N-(5-(((3-AMINO-3-IMINOPROPYL)AMINO)CARBONYL)-1-METHYL-1H-PYRROL-3-YL)-4-(((4-((4-(BIS(2-CHLOROETHYL)AMINO)BENZOYL)AMINO)-1-METHYL-1H-PYRROL-2-YL)CARBONYL)AMINO)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE HYDROCHLORIDE
Systematic Name English
FCE-24517
Code English
Code System Code Type Description
FDA UNII
JWV8AC9E4V
Created by admin on Fri Dec 15 15:39:14 GMT 2023 , Edited by admin on Fri Dec 15 15:39:14 GMT 2023
PRIMARY
CAS
118438-45-2
Created by admin on Fri Dec 15 15:39:14 GMT 2023 , Edited by admin on Fri Dec 15 15:39:14 GMT 2023
PRIMARY
DRUG BANK
DBSALT002880
Created by admin on Fri Dec 15 15:39:14 GMT 2023 , Edited by admin on Fri Dec 15 15:39:14 GMT 2023
PRIMARY
PUBCHEM
6918104
Created by admin on Fri Dec 15 15:39:14 GMT 2023 , Edited by admin on Fri Dec 15 15:39:14 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY